M. Buti Et Al. , "Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment," International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , vol.70, Vienna, Austria, 2019
Buti, M. Et Al. 2019. Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment. International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , (Vienna, Austria).
Buti, M., Izumi, N., Lim, Y., Janssen, H., Kao, J., Streinu-Cercel, A., ... Nurmukhametova, E.(2019). Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment . International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria
Buti, Maria Et Al. "Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment," International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 2019
Buti, Maria Et Al. "Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment." International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , Vienna, Austria, 2019
Buti, M. Et Al. (2019) . "Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment." International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , Vienna, Austria.
@conferencepaper{conferencepaper, author={Maria Buti Et Al. }, title={Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment}, congress name={International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)}, city={Vienna}, country={Austria}, year={2019}}